ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions
View by Date

Wednesday, November 16, 2016

9:00AM-10:30AM
Abstract Number: 3149
“Early Use of Subcutaneous MTX Monotherapy Vs. MTX Oral or Combination Therapy Significantly Delays Time to Initiating Biologics in Early RA
Rheumatoid Arthritis – Clinical Aspects VI: Management of Early Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 3128
A Longitudinal Dual Energy Computed Tomography Study on the Effect of Urate Lowering Therapies on the Reduction of Tophus Burden in Patients with Chronic Gout
Metabolic and Crystal Arthropathies II: Clinical Practice
9:00AM-10:30AM
Abstract Number: 3156
Adding MRI of the Spine to the ASAS Classification Criteria for Axial Spondyloarthritis, Redundant or Beneficial? Results from the Spondyloarthritis Caught Early (SPACE)-Cohort
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment V: Imaging of Spondyloarthritis
9:00AM-10:30AM
Abstract Number: 3184
Antiphospoholipid Antibodies in Giant Cell Arteritis. What Can They Tell Us?
Vasculitis IV: Diagnosis and Assessment of Disease Activity
9:00AM-10:30AM
Abstract Number: 3174
Apremilast Attenuates the Fibrogenic Phenotype of Dermal Fibroblasts from Patients with Systemic Sclerosis, Contributing to the Prevention of the Progression of Experimental Dermal Fibrosis
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics II
9:00AM-10:30AM
Abstract Number: 3154
Assessing Bone Erosions in the Metatarsophalangeal Joints of Patients with Early Rheumatoid Arthritis:  a Comparison Between MRI and Ultrasound
Rheumatoid Arthritis – Clinical Aspects VI: Management of Early Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 3137
Assessing System-Level Performance Measures for Early Rheumatoid Arthritis in a Large Multicenter Cross-Country Prospective 8-Year Observational Cohort Study
Quality Measures and Quality of Care II
9:00AM-10:30AM
Abstract Number: 3140
Assessment of American College of Rheumatology Gout Quality Measures at a University Practice Plan
Quality Measures and Quality of Care II
9:00AM-10:30AM
Abstract Number: 3170
Association Between Insulin Resistance, Subclinical Artheriosclerosis and Activity/Damage Status in Systemic Lupus Erythematosus Patients
Systemic Lupus Erythematosus – Clinical Aspects and Treatment V: Damage and Morbidity
9:00AM-10:30AM
Abstract Number: 3133
Association Between Quantitatively Measured Infrapatellar Fat Pad High Signal Intensity Alteration and Knee Structural and Symptomatic Abnormalities in Patients with Symptomatic Knee Osteoarthritis
Osteoarthritis – Clinical Aspect II: Treatment and Imaging
9:00AM-10:30AM
Abstract Number: 3182
Attenuation of Fluorine-18-Fluorodeoxyglucose Uptake in Large Vessel Giant Cell Arteritis after Short-Term High-Dose Steroid Treatment – a Diagnostic Window of Opportunity
Vasculitis IV: Diagnosis and Assessment of Disease Activity
9:00AM-10:30AM
Abstract Number: 3153
Automated Cell Phone Monitoring of Disease Activity and Medication Adherence in Early Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects VI: Management of Early Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 3139
Breaking the Cycle: Analyzing Preventable Hospital Admissions Due to Gout
Quality Measures and Quality of Care II
9:00AM-10:30AM
Abstract Number: 3114
Cardiorespiratory Fitness in Children with Juvenile Idiopathic Arthritis Treated in the Biological Era Is Comparable with Controls- a Cross-Sectional Study
ACR/ARHP Combined Abstract Session: Pediatric Rheumatology
9:00AM-10:30AM
Abstract Number: 3119
Complete Whole Genome Transcriptome, DNA Methylation, and Histone Mark Analysis of Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS) Reveals a Distinctive Epigenetic Landscape and Critical Pathogenic Pathways
Genetics, Genomics and Proteomics II
  • 1
  • 2
  • 3
  • …
  • 10
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology